10 August 2026
10 August 2026
The procedure was carried out at the CARTI Cancer Center Little Rock, Arkansas, US.
The trial will assess the tolerability and safety of single ascending doses of NBIP-'1968 in overweight or obese adults.
ENERGI-F703DFU is currently in Phase III clinical development in both Taiwan and the US.
The molecular diagnostics company's concurrent CLIA Waiver by Application, if granted, would allow testing in decentralised point-of-care settings.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
